Skip to content
HowShorted

Gossamer Bio, Inc. short interest in 2022

In 2022, Gossamer Bio, Inc.'s disclosed short interest ran from 14.75% of shares outstanding on 14 Jan 2022 to 28.46% on 30 Dec 2022, a change of +13.71 percentage points. The year's high was 28.46% on 30 Dec 2022 and its low 13.65% on 29 Apr 2022, averaging 17.30% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.06 days on 15 Mar 2022. Full history: Gossamer Bio, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Gossamer Bio, Inc. in 2022

2022 in figures

Start of year
14.75% (14 Jan 2022)
End of year
28.46% (30 Dec 2022)
Change
+13.71 pp
High
28.46% (30 Dec 2022)
Low
13.65% (29 Apr 2022)
Average
17.30%
Highest days to cover
23.06 (15 Mar 2022)
SEC filings marked
9

Every report in 2022

Gossamer Bio, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202214.75%19.70
31 Jan 202216.13%12.42
15 Feb 202216.25%21.74
28 Feb 202215.90%18.58
15 Mar 202215.77%23.0610-K filed, results (8-K)
31 Mar 202215.48%21.65
14 Apr 202215.07%21.57
29 Apr 202213.65%6.28results (8-K)
13 May 202214.91%10.5010-Q filed, results (8-K)
31 May 202214.54%17.37
15 Jun 202215.68%23.05
30 Jun 202215.37%15.13
15 Jul 202217.52%4.01
29 Jul 202218.82%9.14
15 Aug 202216.47%11.3510-Q filed, results (8-K)
31 Aug 202217.16%22.09
15 Sep 202217.68%19.18
30 Sep 202218.49%12.39
14 Oct 202218.80%13.14
31 Oct 202220.09%12.22
15 Nov 202220.25%16.7910-Q filed, results (8-K)
30 Nov 202222.73%10.39
15 Dec 202215.25%1.14
30 Dec 202228.46%2.71

See also: Gossamer Bio, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.